- Home
- INKT vs INMB Comparison
INKT vs INMB Comparison
Compare INKT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- INMB
- Stock Information
- Founded
- INKT 2017
- INMB 2015
- Country
- INKT United States
- INMB United States
- Employees
- INKT N/A
- INMB N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- INMB Health Care
- Exchange
- INKT Nasdaq
- INMB Nasdaq
- Market Cap
- INKT 75.7M
- INMB 68.9M
- IPO Year
- INKT 2021
- INMB 2019
- Fundamental
- Price
- INKT $17.18
- INMB $2.92
- Analyst Decision
- INKT Hold
- INMB Buy
- Analyst Count
- INKT 3
- INMB 4
- Target Price
- INKT $37.50
- INMB $9.53
- AVG Volume (30 Days)
- INKT 2.9M
- INMB 4.5M
- Earning Date
- INKT 08-12-2025
- INMB 08-04-2025
- Dividend Yield
- INKT N/A
- INMB N/A
- EPS Growth
- INKT N/A
- INMB N/A
- EPS
- INKT N/A
- INMB N/A
- Revenue
- INKT N/A
- INMB $50,000.00
- Revenue This Year
- INKT N/A
- INMB $203.60
- Revenue Next Year
- INKT N/A
- INMB $13,122.47
- P/E Ratio
- INKT N/A
- INMB N/A
- Revenue Growth
- INKT N/A
- INMB N/A
- 52 Week Low
- INKT $4.56
- INMB $1.89
- 52 Week High
- INKT $76.00
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- INKT 51.36
- INMB 41.08
- Support Level
- INKT $18.38
- INMB $2.62
- Resistance Level
- INKT $20.25
- INMB $3.24
- Average True Range (ATR)
- INKT 8.07
- INMB 0.24
- MACD
- INKT -1.01
- INMB 0.25
- Stochastic Oscillator
- INKT 16.15
- INMB 72.34
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.